<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700138</url>
  </required_header>
  <id_info>
    <org_study_id>6621</org_study_id>
    <nct_id>NCT03700138</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies</brief_title>
  <acronym>TINISS</acronym>
  <official_title>Prospective, Randomised, Placebo-controlled Study of Polyvalent Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To summarise, the peripheral neurological complications experienced by patients with primary&#xD;
      Sjögren's syndrome are particularly bothersome since they are common and often result in&#xD;
      significant disability related to pain or motor impairment. There is currently no standard&#xD;
      treatment for these patients.&#xD;
&#xD;
      As these neuropathies are caused by an immune system dysfunction, which is related to a&#xD;
      variety of different pathogenic mechanisms, the use of immunosuppressant or immunomodulator&#xD;
      drugs is often justified.&#xD;
&#xD;
      With the exception of the vascularitis-related multiplex mononeuropathies, other pSS-related&#xD;
      neuropathies could be suitable candidates for IV Ig treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of at least 20% over placebo of numerical Pain Scale</measure>
    <time_frame>At week 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of at least 20% over placebo with the R-DS scale (Rasch-built Overall Disability Scale)</measure>
    <time_frame>At week 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's quality of life, fatigue, and Sicca syndrome intensity.</measure>
    <time_frame>Weeks 11</time_frame>
    <description>o Quality of life scale (SF 36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's quality of life, fatigue, and Sicca syndrome intensity.</measure>
    <time_frame>Weeks 11</time_frame>
    <description>o HAD depression score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's quality of life, fatigue, and Sicca syndrome intensity.</measure>
    <time_frame>Weeks 11</time_frame>
    <description>o Numerical Fatigue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's quality of life, fatigue, and Sicca syndrome intensity.</measure>
    <time_frame>Weeks 11</time_frame>
    <description>o A fatigue scale (EMIF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's quality of life, fatigue, and Sicca syndrome intensity. intensity.</measure>
    <time_frame>Weeks 11</time_frame>
    <description>o Numerical Dry mouth Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's quality of life, fatigue, and Sicca syndrome intensity. intensity.</measure>
    <time_frame>Weeks11</time_frame>
    <description>o Numerical Dry eye Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's quality of life, fatigue, and Sicca syndrome intensity.</measure>
    <time_frame>Weeks 11</time_frame>
    <description>o ESSPRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's quality of life, fatigue, and Sicca syndrome intensity.</measure>
    <time_frame>Weeks 11</time_frame>
    <description>o ESSDAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate intensity of the IV Ig effect on neurological scales</measure>
    <time_frame>Weeks 11</time_frame>
    <description>o Overall Neuropathy Limitations Scale (ONLS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Primary Sjögren's Syndrome Painful Sensory Neuropathies</condition>
  <arm_group>
    <arm_group_label>Privigen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TThe treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 6 weeks, with a total of 3 perfusions administered (W0, W4, W8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Privigen® 100mg/ml at the dose of 2g/kg of body weight</intervention_name>
    <description>The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).</description>
    <arm_group_label>Privigen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0,9%</intervention_name>
    <description>The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and &lt; 80 years&#xD;
&#xD;
          -  Primary Sjögren's syndrome defined as per the European and American criteria (5)&#xD;
&#xD;
          -  Peripheral neuropathy clinically defined:&#xD;
&#xD;
               -  Pure sensitive (lymph node disease) or sensorimotor neuropathies with INCAT score&#xD;
                  of at least 2&#xD;
&#xD;
               -  Proved EMG&#xD;
&#xD;
          -  Renal function, and viral evaluation (VIH and hepatitis serology) :&#xD;
&#xD;
             *Clairance &gt; 50 (In case of biological abnormality, the second dosage can be scheduled&#xD;
             within 2 weeks)&#xD;
&#xD;
          -  Effective contraception during the study period&#xD;
&#xD;
          -  Patient capable of understanding information about the study and of giving his/her&#xD;
             consent&#xD;
&#xD;
          -  Patient informed of the preliminary medical exam results&#xD;
&#xD;
          -  Patient with healthcare insurance&#xD;
&#xD;
          -  Written consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral neurological damage of the type vascularitis-related multiplex&#xD;
             mononeuropathy&#xD;
&#xD;
          -  Small fibers neuropathy&#xD;
&#xD;
          -  Neuropathy suspected of being related to alcohol, diabetes or post-chemotherapy&#xD;
&#xD;
          -  Chronic viral infection (HCV, HBV, HIV, etc.)&#xD;
&#xD;
          -  Prior treatment with polyvalent intravenous immunoglobulins in the 6 months preceding&#xD;
             the study&#xD;
&#xD;
          -  Corticosteroid treatment at a dose greater than 20 mg/d of prednisone equivalent or no&#xD;
             stable dose for at least 1 month before inclusion&#xD;
&#xD;
          -  Conventional immunosuppressant treatment with azathioprin, cyclophosphamide or&#xD;
             mycophenolate mofetil on-going or interrupted less than one month before inclusion&#xD;
&#xD;
          -  Rituximab or other biotherapy (belimumab, tocilizumab, …) less than 6 months before&#xD;
             the start of the study treatment&#xD;
&#xD;
          -  Immunomodulating treatment with methotrexate no stable dose for at least 2 months&#xD;
             before inclusion&#xD;
&#xD;
          -  Hydroxychloroquine no stable dose for at least 3 months before inclusion&#xD;
&#xD;
          -  Pilocarpine hydrochloride secretagogue treatment no stable dose for at least one month&#xD;
             before inclusion&#xD;
&#xD;
          -  Treatment with amitriptyline, clomipramine, carbamazepine, clonazepam, pregabaline,&#xD;
             duloxetine or gabapentine if the dose has not been stable for at least one month&#xD;
             before inclusion (possible dose reduction to be documented).&#xD;
&#xD;
          -  renal clairance &lt; 50 ml/mn&#xD;
&#xD;
          -  HIV seropositivity&#xD;
&#xD;
          -  HBV, or HCV viral replication&#xD;
&#xD;
          -  Contraindication to the use of IV Ig: h Hypersensitivity to the active substance or to&#xD;
             any of the excipients; hypersensitivity to human immunoglobulins, especially in&#xD;
             patients with antibodies against IgA; patients with hyperprolinaemia.&#xD;
&#xD;
          -  Contraindication to the use of Nacl&#xD;
&#xD;
          -  Immunization with live attenuated vaccine within 2 weeks prior to inclusion&#xD;
&#xD;
          -  Participation in a clinical study with an investigational product with an exclusion&#xD;
             period&#xD;
&#xD;
          -  Women of child bearing potential or intends to become pregnant, unless they are using&#xD;
             an effective method of birth control* and a βHCG blood test negative&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Patient under legal guardianship&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques-Eric Jacques-Eric, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques-Eric GOTTENBERG, MD</last_name>
    <phone>03 88 12 79 53</phone>
    <phone_ext>0033</phone_ext>
    <email>jacques-eric.gottenberg@chru-strabourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jérôme DE SEZE, MD</last_name>
    <phone>03 88 12 85 43</phone>
    <phone_ext>0033</phone_ext>
    <email>Jerome.DESEZE@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, Strasbourg, france</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques -Eric Gottenberg, MD</last_name>
      <phone>03 88 12 79 53</phone>
      <phone_ext>0033</phone_ext>
      <email>jacques-eric.gottenberg@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

